Condition (MeSH)
Sudden Unexpected Death in Epilepsy
ClinicalTrials.gov lists 22 trials for Sudden Unexpected Death in Epilepsy or a narrower condition beneath it. MedtronicNeuro has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 22 trials are tagged with Sudden Unexpected Death in Epilepsy itself; the rest are tagged with a narrower condition beneath it.
When did Sudden Unexpected Death in Epilepsy trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 2 |
| 2022 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 3 |
| 2015 | 2 |
| 2014 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 35 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 10 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sudden Unexpected Death in Epilepsy trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 6 |
| Observational | 11 |
How many Sudden Unexpected Death in Epilepsy trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 9 |
| Active, not recruiting | 1 |
| Completed | 8 |
| Terminated | 2 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sudden Unexpected Death in Epilepsy trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| MedtronicNeuro | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Prozac Pulvules 40 mg | 2 |
| naloxone IM | 1 |
| Medicinal gas - oxygen (Nippon Gases 200 bar) | 1 |
| Fenfluramine treatment (Fintepla) | 1 |
| 2-phenylethanol rose scent | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Sudden Unexpected Death in Epilepsy? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. | Seizure | 2021 | Yes |
| Cardiac arrhythmias and sudden unexpected death in epilepsy: Results of long-term monitoring. | Heart rhythm | 2021 | Yes |
| Improving Patient-Centered Communication about Sudden Unexpected Death in Epilepsy through Computerized Clinical Decision Support. | Applied clinical informatics | 2021 | Yes |
| Mortality in tuberous sclerosis complex. | Epilepsy & behavior : E&B | 2021 | Yes |
| The Epidemiology of Epilepsy. | Neuroepidemiology | 2020 | Yes |
Showing 5 of 10 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.